Mycophenilic Acid has 23 known drug interactions based on U.S. FDA drug labeling data. 9 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Azathioprine, Bile Acid Binding Resins, Cholestyramine Light. Patients taking Mycophenilic Acid should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 23
- Major
- 9
- Moderate
- 11
Major (9)
- Mycophenilic Acid + Azathioprine— Competition for purine metabolism; concomitant administration is not recommended.
- Mycophenilic Acid + Bile Acid Binding Resins— May decrease MPA concentrations by interfering with enterohepatic recirculation; concomitant use is not recommended.
- Mycophenilic Acid + Cholestyramine Light— May decrease mycophenolic acid concentrations through interference with enterohepatic recirculation; concomitant use is …
- Mycophenilic Acid + Cns-Active Drugs— May decrease mycophenolic acid concentrations; concomitant use is not recommended.
- Mycophenilic Acid + Metronidazole— May decrease mycophenolic acid concentrations; concomitant use is not recommended.
- Mycophenilic Acid + Norfloxacin— May decrease mycophenolic acid concentrations; concomitant use is not recommended.
- Mycophenilic Acid + Oral Contraceptives— May reduce effectiveness of oral contraceptives; additional barrier contraceptive methods must be used.
- Mycophenilic Acid + Rifampin— May decrease mycophenolic acid concentrations; concomitant use is not recommended unless benefit outweighs risk.
- Mycophenilic Acid + Sevelamer— May decrease mycophenolic acid plasma concentrations; concomitant use is not recommended.
Moderate (11)
- Mycophenilic Acid + Acyclovir— ( 5.2 , 7.8 ) Acyclovir, Valacyclovir, Ganciclovir, Valganciclovir, and Other Drugs that Undergo Renal Tubular Secretion…
- Mycophenilic Acid + Aluminum & Magnesium Hydroxides— Decreases concentrations of MPA; concomitant use is not recommended.
- Mycophenilic Acid + Aluminum Hydroxide— Decreases concentrations of mycophenolic acid; concomitant use is not recommended.
- Mycophenilic Acid + Colestipol Hydrochloride— Colestipol may reduce mycophenolic acid exposure and potentially reduce efficacy of mycophenolate mofetil by binding bil…
- Mycophenilic Acid + Cyclosporine— May decrease MPA concentrations; exercise caution when switching between drugs.
- Mycophenilic Acid + Ganciclovir— ( 5.2 , 7.8 ) Acyclovir, Valacyclovir, Ganciclovir, Valganciclovir, and Other Drugs that Undergo Renal Tubular Secretion…
- Mycophenilic Acid + Magnesium Hydroxide— Decreases concentrations of mycophenolic acid; concomitant use is not recommended.
- Mycophenilic Acid + Tacrolimus— Can increase MPA exposure after crossover from cyclosporine to tacrolimus. Monitor for MPA-related adverse reactions and…
- Mycophenilic Acid + Tacrolimus Extended-Release Capsules— MPA exposure is higher with tacrolimus extended-release capsules than with cyclosporine. Monitor for MPA-associated adve…
- Mycophenilic Acid + Valacyclovir— ( 5.2 , 7.8 ) Acyclovir, Valacyclovir, Ganciclovir, Valganciclovir, and Other Drugs that Undergo Renal Tubular Secretion…
- Mycophenilic Acid + Valganciclovir— ( 5.2 , 7.8 ) Acyclovir, Valacyclovir, Ganciclovir, Valganciclovir, and Other Drugs that Undergo Renal Tubular Secretion…